UNSPSC 51373425: Chlorpheniramine/codeine/phenylephrine/potassium iodide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373425 Chlorpheniramine/codeine/phenylephrine/potassium iodide is a Commodity code that covers prescription pharmaceuticals and controlled substances procured by state and local health and correctional agencies. Recent opportunities under this code show state and local governments buying parenteral products including intravenous solutions, total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN) preparations, and naloxone for emergency medical and harm-reduction use. The Washington State Department of Corrections and Seminole County, Florida represent the issuing-body mix: state correctional systems and county public health departments both source these products to serve incarcerated populations and community members. Suppliers must meet pharmaceutical licensing, insurance, and compliance requirements including drug-free workplace certification and E-Verify verification, and state correctional facilities enforce strict delivery timelines — parenteral nutrition bags within 24 hours of order and other parenteral products within 8 hours for initial supply.

Washington State and Florida dominate recent activity under the code. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026 for parenteral products and equipment across eight correctional facilities, with response due October 7, 2026 and DOC planning to award multiple contractors across three regional zones (West, Central, and East). The contract runs through June 30, 2030 with fixed pricing required for the initial two-year term. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems, with quarterly deliveries and a two-year initial term plus one-year renewal option. Both solicitations encourage or prioritize small, minority-owned, women-owned, and veteran-owned business participation where applicable, and both require commercial general liability and professional liability insurance.